Way back for fructose and liver metabolism: Bench side to molecular insights

World Journal of Gastroenterology

Volumn 18, Issue 45, 2012, Pages 6552-6559

  Rebollo, Alba ^a   Roglans, Núria ^a,b   Alegret, Marta ^a,b   Laguna, Juan C ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Clinical studies; Dyslipidemia; Experimental studies; Hypertension; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; Sweetened beverages

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CARBOHYDRATE; FRUCTOKINASE; FRUCTOSE; GLUCOSE; INSULIN RECEPTOR SUBSTRATE 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIRTUIN 1; SUCROSE; TRIACYLGLYCEROL; X BOX BINDING PROTEIN 1;

BEVERAGE; CALORIC RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FRUCTOSE METABOLISM; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER METABOLISM; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; REVIEW; RISK FACTOR; SUGAR INTAKE;

EID: 84873908527     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i45.6552     Document Type: Review

References (72)

1. Lustig RH, Schmidt LA, Brindis CD. Public health: The toxic truth about sugar. Nature 2012; 482: 27-29
2. Aller EE, Abete I, Astrup A, Martinez JA, van Baak MA. Starches, sugars and obesity. Nutrients 2011; 3: 341-369
3. Dallongeville J, Charbonnel B, Desprès JP. Sugar-sweetened beverages and cardiometabolic risk. Presse Med 2011; 40: 910-915
4. Alegret M, Roglans N, Laguna JC. Fructose consumption and leptin resistance: What have we learnt from animal studies? In: Hemling RM, Belkin AT, editors. Leptin: Hormonal Functions, dysfunctions and clinical uses. Hauppauge, NY, USA: Nova Science Publishers Inc, 2011: 210-230
5. Hu FB, Malik VS. Sugar-sweetened beverages and risk of obesity and type 2 diabetes: epidemiologic evidence. Physiol Behav 2010; 100: 47-54
6. Malik VS, Popkin BM, Bray GA, Després JP, Hu FB. Sugarsweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 2010; 121: 1356-1364
7. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010; 7: 251-264
8. Tappy L, Lê KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010; 90: 23-46
9. Lanaspa MA, Tapia E, Soto V, Sautin Y, Sánchez-Lozada LG. Uric acid and fructose: potential biological mechanisms. Semin Nephrol 2011; 31: 426-432
10. Soleimani M. Dietary fructose, salt absorption and hypertension in metabolic syndrome: towards a new paradigm. Acta Physiol (Oxf) 2011; 201: 55-62
11. Browning JD, Baker JA, Rogers T, Davis J, Satapati S, Burgess SC. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 2011; 93: 1048-1052
12. Maersk M, Belza A, Stødkilde-Jørgensen H, Ringgaard S, Chabanova E, Thomsen H, Pedersen SB, Astrup A, Richelsen B. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr 2012; 95: 283-289
13. Silbernagel G, Lütjohann D, Machann J, Meichsner S, Kantartzis K, Schick F, Häring HU, Stefan N, Fritsche A. Cholesterol synthesis is associated with hepatic lipid content and dependent on fructose/glucose intake in healthy humans. Exp Diabetes Res 2012; 2012: 361863
14. Stanhope KL, Bremer AA, Medici V, Nakajima K, Ito Y, Nakano T, Chen G, Fong TH, Lee V, Menorca RI, Keim NL, Havel PJ. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab 2011; 96: E1596-E1605
15. de Koning L, Malik VS, Rimm EB, Willett WC, Hu FB. Sugar-sweetened and artificially sweetened beverage consumption and risk of type 2 diabetes in men. Am J Clin Nutr 2011; 93: 1321-1327
16. Silbernagel G, Machann J, Unmuth S, Schick F, Stefan N, Häring HU, Fritsche A. Effects of 4-week very-highfructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial. Br J Nutr 2011; 106: 79-86
17. Cox CL, Stanhope KL, Schwarz JM, Graham JL, Hatcher B, Griffen SC, Bremer AA, Berglund L, McGahan JP, Havel PJ, Keim NL. Consumption of fructose-sweetened beverages for 10 weeks reduces net fat oxidation and energy expenditure in overweight/obese men and women. Eur J Clin Nutr 2012; 66: 201-208
18. Maier IB, Stricker L, Ozel Y, Wagnerberger S, Bischoff SC, Bergheim I. A low fructose diet in the treatment of pediatric obesity: a pilot study. Pediatr Int 2011; 53: 303-308
19. Pollock NK, Bundy V, Kanto W, Davis CL, Bernard PJ, Zhu H, Gutin B, Dong Y. Greater fructose consumption is associated with cardiometabolic risk markers and visceral adiposity in adolescents. J Nutr 2012; 142: 251-257
20. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010; 74: 213-220
21. Cox CL, Stanhope KL, Schwarz JM, Graham JL, Hatcher B, Griffen SC, Bremer AA, Berglund L, McGahan JP, Keim NL, Havel PJ. Circulating concentrations of monocyte chemoattractant protein-1, plasminogen activator inhibitor-1, and soluble leukocyte adhesion molecule-1 in overweight/obese men and women consuming fructose-or glucose-sweetened beverages for 10 weeks. J Clin Endocrinol Metab 2011; 96: E2034-E2038
22. Brown IJ, Stamler J, Van Horn L, Robertson CE, Chan Q, Dyer AR, Huang CC, Rodriguez BL, Zhao L, Daviglus ML, Ueshima H, Elliott P. Sugar-sweetened beverage, sugar intake of individuals, and their blood pressure: international study of macro/micronutrients and blood pressure. Hypertension 2011; 57: 695-701
23. Liu H, Heaney AP. Refined fructose and cancer. Expert Opin Ther Targets 2011; 15: 1049-1059
24. Seneff S, Wainwright G, Mascitelli L. Nutrition and Alzheimer's disease: the detrimental role of a high carbohydrate diet. Eur J Intern Med 2011; 22: 134-140
25. Friberg E, Wallin A, Wolk A. Sucrose, high-sugar foods, and risk of endometrial cancer--a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1831-1837
26. Ye X, Gao X, Scott T, Tucker KL. Habitual sugar intake and cognitive function among middle-aged and older Puerto Ricans without diabetes. Br J Nutr 2011; 106: 1423-1432
27. Bruggeman EC, Li C, Ross AP, Doherty JM, Williams BF, Frantz KJ, Parent MB. A high fructose diet does not affect amphetamine self-administration or spatial water maze learning and memory in female rats. Pharmacol Biochem Behav 2011; 99: 356-364
28. Ross AP, Bruggeman EC, Kasumu AW, Mielke JG, Parent MB. Non-alcoholic fatty liver disease impairs hippocampaldependent memory in male rats. Physiol Behav 2012; 106: 133-141
29. Bouchard-Thomassin AA, Lachance D, Drolet MC, Couet J, Arsenault M. A high-fructose diet worsens eccentric left ventricular hypertrophy in experimental volume overload. Am J Physiol Heart Circ Physiol 2011; 300: H125-H134
30. Zhang J, Zhang BH, Yu YR, Tang CS, Qi YF. Adrenomedullin protects against fructose-induced insulin resistance and myocardial hypertrophy in rats. Peptides 2011; 32: 1415-1421
31. Zhou YB, Zhang J, Cai Y, Teng X, Duan XH, Song JQ, Du J, Tang CS, Qi YF. Insulin resistance induces medial artery calcification in fructose-fed rats. Exp Biol Med (Maywood) 2012; 237: 50-57
32. Guo Q, Mori T, Jiang Y, Hu C, Ohsaki Y, Yoneki Y, Nakamichi T, Ogawa S, Sato H, Ito S. Losartan modulates muscular capillary density and reverses thiazide diureticexacerbated insulin resistance in fructose-fed rats. Hypertens Res 2012; 35: 48-54
33. Hein GJ, Chicco A, Lombardo YB. Fish oil normalizes plasma glucose levels and improves liver carbohydrate metabolism in rats fed a sucrose-rich diet. Lipids 2012; 47: 141-150
34. Silva RJ, Bernardes N, Brito Jde O, Sanches IC, Irigoyen MC, De Angelis K. Simvastatin-induced cardiac autonomic control improvement in fructose-fed female rats. Clinics (Sao Paulo) 2011; 66: 1793-1796
35. Vasudevan H, Yuen VG, McNeill JH. Testosterone-dependent increase in blood pressure is mediated by elevated Cyp4A expression in fructose-fed rats. Mol Cell Biochem 2012; 359: 409-418
36. Chen L, Lan Z, Zhou Y, Li F, Zhang X, Zhang C, Yang Z, Li P. Astilbin attenuates hyperuricemia and ameliorates nephropathy in fructose-induced hyperuricemic rats. Planta Med 2011; 77: 1769-1773
37. Kunde SS, Roede JR, Vos MB, Orr ML, Go YM, Park Y, Ziegler TR, Jones DP. Hepatic oxidative stress in fructoseinduced fatty liver is not caused by sulfur amino acid insufficiency. Nutrients 2011; 3: 987-1002
38. Roncal-Jimenez CA, Lanaspa MA, Rivard CJ, Nakagawa T, Sanchez-Lozada LG, Jalal D, Andres-Hernando A, Tanabe K, Madero M, Li N, Cicerchi C, Mc Fann K, Sautin YY, Johnson RJ. Sucrose induces fatty liver and pancreatic inflammation in male breeder rats independent of excess energy intake. Metabolism 2011; 60: 1259-1270
39. Chen GC, Huang CY, Chang MY, Chen CH, Chen SW, Huang CJ, Chao PM. Two unhealthy dietary habits featuring a high fat content and a sucrose-containing beverage intake, alone or in combination, on inducing metabolic syndrome in Wistar rats and C57BL/6J mice. Metabolism 2011; 60: 155-164
40. London E, Castonguay TW. High fructose diets increase 11β-hydroxysteroid dehydrogenase type 1 in liver and visceral adipose in rats within 24-h exposure. Obesity (Silver Spring) 2011; 19: 925-932
41. Morris M, Araujo IC, Pohlman RL, Marques MC, Rodwan NS, Farah VM. Timing of fructose intake: an important regulator of adiposity. Clin Exp Pharmacol Physiol 2012; 39: 57-62
42. Spruss A, Kanuri G, Uebel K, Bischoff SC, Bergheim I. Role of the inducible nitric oxide synthase in the onset of fructoseinduced steatosis in mice. Antioxid Redox Signal 2011; 14: 2121-2135
43. Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I. Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2011; 22: 527-534
44. Samuel VT. Fructose induced lipogenesis: from sugar to fat to insulin resistance. Trends Endocrinol Metab 2011; 22: 60-65
45. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009; 19: 291-302
46. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2009; 11: 188-195
47. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-471
48. Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-718
49. Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643-1647
50. Vilà L, Rebollo A, Ad{stroke}alsteisson GS, Alegret M, Merlos M, Roglans N, Laguna JC. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol 2011; 251: 32-40
51. Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, Egido J. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-261
52. Planavila A, Laguna JC, Vázquez-Carrera M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factorkappa B activation. Biochim Biophys Acta 2005; 1687: 76-83
53. Korieh A, Crouzoulon G. Dietary regulation of fructose metabolism in the intestine and in the liver of the rat. Duration of the effects of a high fructose diet after the return to the standard diet. Arch Int Physiol Biochim Biophys 1991; 99: 455-460
54. Vilà L, Roglans N, Perna V, Sánchez RM, Vázquez-Carrera M, Alegret M, Laguna JC. Liver AMP/ATP ratio and fructokinase expression are related to gender differences in AMPK activity and glucose intolerance in rats ingesting liquid fructose. J Nutr Biochem 2011; 22: 741-751
55. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-999
56. Alegret M, Ferrando R, Vázquez M, Adzet T, Merlos M, Laguna JC. Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. Br J Pharmacol 1994; 112: 551-556
57. Roglans N, Vilà L, Farré M, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC. Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructosefed rats. Hepatology 2007; 45: 778-788
58. Vilà L, Roglans N, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC. Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism. Hepatology 2008; 48: 1506-1516
59. Kim SK, Novak RF. The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol Ther 2007; 113: 88-120
60. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012; 92: 689-737
61. Hanke N, Scheibe RJ, Manukjan G, Ewers D, Umeda PK, Chang KC, Kubis HP, Gros G, Meissner JD. Gene regulation mediating fiber-type transformation in skeletal muscle cells is partly glucose-and ChREBP-dependent. Biochim Biophys Acta 2011; 1813: 377-389
62. Volynets V, Spruss A, Kanuri G, Wagnerberger S, Bischoff SC, Bergheim I. Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. J Lipid Res 2010; 51: 3414-3424
63. Li Y, Inoki K, Vacratsis P, Guan KL. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J Biol Chem 2003; 278: 13663-13671
64. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8: 393-412
65. Guo S, Dunn SL, White MF. The reciprocal stability of FOXO1 and IRS2 creates a regulatory circuit that controls insulin signaling. Mol Endocrinol 2006; 20: 3389-3399
66. Zhou Y, Lee J, Reno CM, Sun C, Park SW, Chung J, Lee J, Fisher SJ, White MF, Biddinger SB, Ozcan U. Regulation of glucose homeostasis through a XBP-1-FoxO1 interaction. Nat Med 2011; 17: 356-365
67. Pfaffenbach KT, Nivala AM, Reese L, Ellis F, Wang D, Wei Y, Pagliassotti MJ. Rapamycin inhibits postprandial-mediated X-box-binding protein-1 splicing in rat liver. J Nutr 2010; 140: 879-884
68. Lee J, Sun C, Zhou Y, Lee J, Gokalp D, Herrema H, Park SW, Davis RJ, Ozcan U. p38 MAPK-mediated regulation of Xbp1s is crucial for glucose homeostasis. Nat Med 2011; 17: 1251-1260
69. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 2006; 4: 107-110
70. Rodríguez-Calvo R, Barroso E, Serrano L, Coll T, Sánchez RM, Merlos M, Palomer X, Laguna JC, Vázquez-Carrera M. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology 2009; 49: 106-115
71. Pashkov V, Huang J, Parameswara VK, Kedzierski W, Kurr-asch DM, Tall GG, Esser V, Gerard RD, Uyeda K, Towle HC, Wilkie TM. Regulator of G protein signaling (RGS16) inhibits hepatic fatty acid oxidation in a carbohydrate response element-binding protein (ChREBP)-dependent manner. J Biol Chem 2011; 286: 15116-15125
72. Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBPdependent hepatic steatosis in mice. J Clin Invest 2010; 120: 4316-4331